Aeonbiopharma
NYSE: AEON1 known investors
AEON Biopharma develops ABP-450 (prabotulinumtoxinA), a branded biosimilar to BOTOX®, targeting therapeutic indications for neuromuscular conditions. The company uses the FDA's biosimilar pathway to expand access to therapeutic botulinum toxin treatments for patients, providers, and payers.